Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down Following Analyst Downgrade

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s share price gapped down before the market opened on Tuesday after BTIG Research lowered their price target on the stock from $40.00 to $21.00. The stock had previously closed at $18.95, but opened at $14.27. BTIG Research currently has a buy rating on the stock. Theravance Biopharma shares last traded at $14.0130, with a volume of 1,876,408 shares trading hands.

Other analysts have also recently issued research reports about the stock. Oppenheimer assumed coverage on shares of Theravance Biopharma in a research report on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 price objective for the company. HC Wainwright boosted their target price on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday. Wall Street Zen lowered Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Theravance Biopharma in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Theravance Biopharma presently has a consensus rating of “Buy” and a consensus price target of $25.40.

Trending Headlines about Theravance Biopharma

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company reports a strong cash position (about $326.5M at Q4 2025 and ~ $400M expected at end-Q1 2026 including milestones), no debt, and confidence in a $100M 2026 TRELEGY milestone — provides near-term runway. PR Newswire Release
• Positive Sentiment: Board announced accelerated strategic review and a restructuring expected to cut the cost base by ~60% (~$70M), targeting $60–70M of annualized cash flow; company is narrowing to a portfolio focused on YUPELRI, which generated durable revenues (FY2025 net sales recognized by Viatris $266.6M, +12% YoY). PR Newswire Release
• Neutral Sentiment: Analyst actions are mixed but still show some institutional support: BTIG cut its price target to $21 but kept a Buy rating, while HC Wainwright recently raised its target to $27 — signals divergent views on post-trial valuation. BTIG / StreetInsider HC Wainwright note
• Negative Sentiment: Topline from the Phase 3 CYPRESS study: ampreloxetine did not meet the primary endpoint (OHSA composite score) in patients with neurogenic orthostatic hypotension due to MSA — the clinical failure removes the lead late‑stage opportunity. Benzinga: Trial Miss
• Negative Sentiment: Management said it is accelerating a strategic review that could include a sale; media report the company is working with advisors (Lazard) — this signals material uncertainty about TBPH’s standalone future and likely near-term volatility. Reuters: Strategic Review
• Negative Sentiment: Market response: shares plunged and trading was briefly halted; unusually large put-option activity suggests elevated short-term bearish positioning and higher volatility. Proactive Investors: Market Reaction

Institutional Investors Weigh In On Theravance Biopharma

Several institutional investors have recently bought and sold shares of TBPH. Quarry LP bought a new position in shares of Theravance Biopharma during the 3rd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd grew its position in Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 515 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Performance

The firm’s 50-day simple moving average is $19.26 and its 200 day simple moving average is $16.88. The stock has a market capitalization of $707.35 million, a P/E ratio of 24.49 and a beta of 0.17.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.